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Abstract: Background: Psoriasis has a significant impact on quality of life (QoL). Sexual life can also be affected, with sexual 
dysfunction being reported by 25-70% of patients. 
oBjectives: To determine the occurrence of sexual dysfunction and evaluate QoL in women with psoriasis. 
Methods: This case-control study included women aged 18-69 years. The validated Brazilian Portuguese versions of the Fe-
male Sexual Function Index (FSFI) and of the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) were admin-
istered to all participants to assess sexual function and QoL, respectively. Patients with psoriasis underwent clinical evaluation 
for the presence of comorbidities, especially psoriatic arthritis and other rheumatic manifestations. Location of lesions and the 
extent of skin involvement were also assessed. 
results: The sample consisted of 150 women, 75 with diagnosis of psoriasis and 75 healthy controls. Prevalence of sexual dys-
function was high in women with psoriasis (58.6% of the sample). Prevalence was statistically higher in women with psoriasis 
than in controls (P = 0.014). The SF-36 domain scores were also lower in women with psoriasis, with role limitations due to 
physical health, limitations due to emotional problems, and mental health being the most affected domains. 
study liMitations: Sample size was calculated to evaluate the association between the occurrence of sexual dysfunction and 
psoriasis, but it did not include the determination of the possible causes of this dysfunction.
conclusions: QoL and sexual function were altered in women with psoriasis and should be taken into consideration when 
assessing disease severity.
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INTRODUCTION
Psoriasis is a chronic systemic inflammatory disease that in-
volves mainly the skin and joints, affecting 1-3% of the world popu-
lation.1-3 In Brazil, there are still no studies on its incidence and prev-
alence, but it is estimated that 1% of the Brazilian population has 
psoriasis.4 Its impact on quality of life (QoL) has been studied since 
the 1970s, when Jobling observed that more than 80% of patients 
presented difficulties in establishing social relations, considered the 
most daunting aspect of their illness.5,6 Since then, interest has in-
creased in the quality of life and psychosocial wellbeing of psoriasis 
patients. Many studies have shown that psoriasis triggers feelings 
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of depression, shame, and anxiety, culminating in social isolation.7-11 
Al-Mazeedi et al. reported that psoriasis inhibited new relations in 
48.2% of patients, and two-thirds were concerned about the reac-
tions and perceptions of others in relation to their condition.8
One of the key points in maintaining QoL, as defined by 
the World Health Organization, is sexuality.12 Sexual dysfunction is 
characterized by lack of adequate functioning of one of the phases 
comprising the sexual cycle. In women, sexual dysfunction is de-
fined as disorders of desire, libido, or arousal, pain or discomfort, 
and anorgasmia.13
Although sexual dysfunction is a common complaint, af-
fecting 30 to 70% of psoriasis patients, few studies have analyzed 
the impact of psoriasis and psoriatic arthritis on quality of sexual 
life, and none has addressed the Brazilian population.14,15 The aim 
of this article was to assess the occurrence of sexual dysfunction in 
psoriasis using a case-control study with Brazilian women.
METHODS
A case-control study was performed with a convenience 
sample consisting of patients with a diagnosis of psoriasis (psoria-
sis group) treated at a specialized Dermatology Outpatient Service 
at Hospital Universitário de Brasília (HUB) and healthy volunteers 
(healthy control group), matched for age, recruited at the Dermatol-
ogy Outpatient Clinic of Hospital das Forças Armadas (HFA) from 
July 2011 to October 2012. The control group consisted of women 
that were accompanying patients at the outpatient clinic and pa-
tients returning for follow-up, previously treated and without clini-
cal complaints at the time of recruitment.
The study was approved by the Institutional Review Board 
of Faculdade de Medicina, Universidade de Brasília (case review 
010/2011).
Inclusion criteria for all the women were: age 18 to 69 years, 
active sexual life, and clinical diagnosis of psoriasis, as determined 
by the same physician, an experienced dermatologist, and or clinical-
pathology study. For the control group, an inclusion criterion was 
the absence of diagnosis of psoriasis or psoriatic arthritis.
Exclusion criteria were: gynecological disorder potentially 
affecting sexual function (including vaginitis, endometriosis, chron-
ic pelvic pain, malignant neoplasm, uterine cervical dystopia, vagi-
nism, and alterations of the pelvic anatomy); pregnancy; prior psy-
chiatric diagnosis or concurrent with psoriasis (depression, anxiety, 
phobias, psychopathy); diagnosis of rheumatic diseases or others 
that course with arthritis (rheumatoid arthritis, spondyloarthritis, 
microcrystalline arthritis), which can cause confounding or doubt as 
to the diagnosis of possible psoriatic arthritis; diagnosis of chronic, 
extensive skin disorders such as dermatitis, pityriasis rubra pilaris, 
bullous dermatoses, vitiligo, ichthyosis, acne grade two or greater, 
and genital mucocutaneous diseases.
After signing informed consent, all participants underwent 
a clinical assessment that recorded epidemiological data like age, 
ethnicity, schooling, and marital status, besides clinical data such as 
past medical history and use of medications. In psoriasis patients, 
the location of the lesions was also verified (genital involvement, 
ungual involvement, and involvement of exposed skin areas, the 
latter defined for purposes of this study as lesions located on the 
face, scalp, and hands) and extent of the disease, assessed by the 
Psoriasis Area Severity Index (PASI).16 Next, patients were submit-
ted to the version validated in Brazilian Portuguese of the Female 
Sexual Function Index (FSFI) and the Medical Outcome Study 36-
item Short Form Health Survey (SF-36).17,18 Finally, women with 
any complaints pertaining to the joints were examined by an ex-
perienced rheumatologist (always the same physician), in order 
to assess the presence of psoriatic arthritis, based on the CASPAR 
classification criteria.19
The FSFI is a questionnaire that aims to assess female sexual 
response through analysis of the five domains of sexual function: 
desire and subjective arousal, lubrication, orgasm, satisfaction, and 
pain/discomfort. Individual scores are obtained by the sum of the 
items that include each domain (simple score), which are multiplied 
by this domain’s factor, furnishing the weighted score. The final 
score (minimum two, maximum 36) is obtained by the sum of the 
weighted scores in each domain. A total score of 26 or less indicates 
greater risk of sexual dysfunction.20
SF-36 is a 36-item questionnaire that assesses eight domains 
of QoL: physical functioning, role physical, bodily pain, gener-
al health, vitality, social functioning, role emotional, and mental 
health. The score for each domain varies from zero to 100, where 
zero is the worst health status and 100 is the best.18 
Statistical analysis
The sample calculation was done initially in a pilot study 
with 67 women (47 with psoriasis and 20 controls), evaluating the 
variables obtained with the desire indices from the FSFI by means 
of the Wilcoxon text with 95% confidence interval, leading to 88% 
test power for a sample of 150 women with a difference of one point.
Analyses of the association between variables used the R 
software, version 2.15.1 (R Foundation for Statistical Computing, 
Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.
org/). The Kolmogorov-Smirnov test for normality was used to veri-
fy whether the sample’s data showed normal distribution. The distri-
bution was considered normal if p>0.05. Analysis of categorical vari-
ables was based on the chi-square test of independence. When data 
for the variables were less than five, the p-value from the Monte Carlo 
simulated Fisher’s exact test was used, as proposed by Hope, 1968.21 
The association between quantitative variables was investigated in 
two ways: a) by means of categorization of the variables, followed by 
analysis using the chi-square test or Monte Carlo simulated p-value; 
b) by calculation of Pearson’s correlation coefficient, when the vari-
ables showed two-tailed normal distribution, or Spearman’s rank 
correlation coefficient for cases that did not show this distribution. 
Finally, analysis of covariance was applied to assess quantitative tar-
get variables from FSFI and SF-36, adjusted for covariables that could 
influence the study’s results. The categories of some covariables were 
grouped so as to increase the model’s explanatory capacity and good-
ness of fit. Statistical significance was set at 5%.
RESULTS
The study’s sample size was 150 women, of whom 75 in 
the control group and 75 in the psoriasis group, both with mean 
age 45 years and standard deviation approximately 12 years. All 
chart 1: Dermatology QoL instrument in Turkish (TQL)
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the patients diagnosed with psoriasis were caucasian or of mixed 
races. The control group included a few black and Asian-descendent 
women, but the vast majority were caucasian or of mixed races 
(92%). In both groups, the majority of women were married, but 
the proportion of unmarried women and those not living with a 
partner (i.e., single, divorced, or widows) was higher (42.66%) in 
the psoriasis group. As for education, the control group included 
predominantly women with more than seven years of schooling, 
while the psoriasis group included mostly those with one to seven 
years of schooling. Only two illiterate women participated in the 
study, both with psoriasis.
As for clinical status of psoriasis, most of the patients pre-
sented psoriasis vulgaris, and for disease site, 20% presented genital 
involvement, 33% ungual involvement, and 30% with lesions on ex-
posed areas. PASI scores varied from 0 to 21.4, with a median score 
of 3.6 (interquartile range, 6.3). Comorbidities were present in 45% 
of the control group and 72% of the psoriasis group. Chi-square test 
showed a statistically significant association between presence of 
comorbidities and psoriasis (p=0.023). Rheumatological assessment 
was performed in 38 of the 75 patients diagnosed with psoriasis, of 
whom 16 had a diagnosis of fibromyalgia, ten of psoriatic arthritis, 
and two of osteoarthritis; 31 patients denied any kind of rheumatic 
manifestation. Tables 1 and 2, respectively, show the psoriasis group’s 
clinical characteristics and analysis of comorbidities.
table 1: Clinical characteristics of psoriasis group
Psoriasis group
Extent of psoriasis (PASI) 0-21.4 (Median 3.6)
Clinical type of psoriasis
 Psoriasis vulgaris 69 (92%)
 Palmoplantar psoriasis 4 (5.3%)
 Guttate psoriasis 1 (1.3%)
 Erythrodermic psoriasis 1 (1.3%)
Ungual involvement
 Present 25 (33.3%)
 Absent 50 (66.6%)
Genital involvement
 Present 15 (20%)
 Absent 55 (73.3%)
 Missing data 5 (6.7%)
Involvement of exposed areas*
 Present 23 (30.7%)
 Absent 48 (64%)
 Missing data 4 (5.3%)
Associated rheumatologic diagnosis
 Fibromyalgia 16 (21.3%)
 Psoriatic arthritis 10 (13.3%)
 Osteoarthritis 2 (2.6%) 
 Others 10 (13.3%)
 Absence of rheumatologic alterations 31 (41.3%)
 Missing data 6 (8%)
table 2: Assessment of comorbidities in the psoriasis group 








54 (72%) 34 (45.3%) 88 
(65.10%)
0.023
SAH 18 (24%) 14 (18.6%) 0.43
DM 14 (18.6%) 8 (10.7%) 0.17
Dyslipidemia 16 (21.3%) 7 (9.3%) 0.042
Absence of 
comorbidity
19 (25.3%) 28 (37.3%) 47 
(34.81%)
Missing data 2 (2.6%) 13 (17.3%)
table 3: Comparison of quality of life (SF-36) between the 
groups with and without psoriasis, adjusted by age, ethnicity, 











Control 72.3 39.1 0.002
Patient 45.0 47.2
BODILY PAIN - 
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Control 70.3 19.9 0.169
Patient 62.8 27.3












Control 69.3 16.5 0.021
Patient 59.6 28.0
SAH – systemic arterial hypertension; DM – diabetes mellitus
* Adjusted for age, schooling, marital status, and ethnicity
*	significance:	p-value	<	0.05
Quality of life indices (SF-36)
Analysis of covariance revealed significantly worse indices 
in the psoriasis group, adjusted for age, skin color, schooling, and 
marital status in the domains role physical (p=0.002), role emotional 
(p=0.029), and mental health (p=0.021) (Table 3). 
table 4: Comparison of FSFI between the groups with and 
without psoriasis, adjusted for age, ethnicity, schooling, and 




DESIRE Control 3.6 1.2 0.019
Patient 3.2 1.3
AROUSAL Control 3.9 1.8 0.001
Patient 2.6 2.2
LUBRICATION Control 4.3 1.9 0.014 
Patient 3.1 2.6
ORGASM Control 4.2 1.8 0.017
Patient 3.1 2.7
SATISFACTION Control 4.6 2.0 0.001
Patient 3.1 2.6
PAIN Control 4.5 2.0 0.012
Patient 3.4 2.7
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Sexual dysfunction (FSFI)
Forty-four patients (58.6%) and 29 controls (38.6%) showed 
FSFI score less than or equal to 26, with a chi-square test with p-val-
ue 0.014, demonstrating higher occurrence of sexual dysfunction in 
psoriasis patients, with 95% confidence.
Analysis of the association between diagnosis of psoriasis 
and each of the domains (desire, arousal, lubrication, orgasm, satis-
faction, and pain), separately, adjusted for age, race, schooling, and 
marital status was done by analysis of covariance. Table 4 shows 
that the statistical difference was maintained, evidencing that the 
score in the control group was higher than in the group of psoriasis 
patients for all the domains.
Sexual dysfunction showed a statistically significant asso-
ciation with the extent of skin involvement (p-value=0.04). Howev-
er, this association was not observed when analyzing the different 
lesion sites by means of the chi-square test: genital involvement 
was present in 25% of the women without sexual dysfunction and 
in 19% of those with sexual dysfunction, p-value=0.55; ungual in-
volvement in 32.3% of women without dysfunction and in 34.1% of 
women with sexual dysfunction, p-value=0.868; and involvement of 
exposed skin areas in 39.3% of women without dysfunction and in 
27.9% of women with sexual dysfunction (p-value=0.32).
The association between sexual dysfunction and comorbidi-
ties was analyzed by the chi-square test in the psoriasis group (66.7% 
of women without dysfunction and 79% of women with sexual dys-
function presented comorbidity) and did not show a statistically sig-
nificant association (p=0.273). As for diagnosis of rheumatic disease, 
assessed in 69 of the 75 patients included in the study, the chi-square 
test showed a p-value of 0.91 (53.6% of women without dysfunction 
and 56.1% of women with sexual dysfunction presented some type 
of rheumatic disease). Although no statistically significant associa-
tion was observed between presence of rheumatic disease concurrent 
with psoriasis and the occurrence of sexual dysfunction, the total FSFI 
score in women with fibromyalgia was lower (mean 15.4) than in the 
remaining of the psoriasis group (mean 19.6).
DISCUSSION
The current study confirmed the impact of psoriasis on 
QoL, demonstrating that the domains assessed with the SF-36 
questionnaire, especially role physical, vitality, role emotional, and 
mental health are worse in women with psoriasis when compared 
to healthy controls. These data are consistent with previous studies 
in the literature.22. 23Al-Mazeedi et al. observed the effect of psoria-
sis on physical activities and reported that open-air activities and 
sun-bathing were affected in half of the cases, and light exercises, 
such as walking, were jeopardized in 77.3% of patients.8 The func-
tional limitation is due mainly to pruritis, irritation, and pain. Pal-
moplantar psoriasis and psoriatic arthritis add a negative effect to 
QoL, since they directly affect activities of daily living.8
According to Chiozza, psoriasis patients, more than pa-
tients with other dermatologic diagnoses, fear social isolation and 
rejection and harbor fantasies of abandonment.24 Approximately 
26% of psoriasis patients report family tensions resulting from the 
disease, 50% limit their participation in sports activities, and 40% 
experience some difficulty in the workplace.25
A recent systematic literature review aimed to assess the 
prevalence of sexual dysfunction in patients with psoriasis and pso-
riatic arthritis, analyzing such factors as depression and extent of 
the disease in this relationship.26 The review analyzed 4,039 psoria-
sis patients, of whom 2,567 were men (63.55%) and 1,472 were wom-
en (36.45%), with age ranging from 23 to 62 years. In all the studies, 
patients were assessed as to sexual function based on self-adminis-
tered questionnaires, and some studies also evaluated psychologi-
cal aspects and QoL. Although the study populations and question-
naires varied, sexual dysfunction was prevalent in all the studies 
(ranging from 22.6% to 71.3%).26
Later publications also addressed the subject, with preva-
lence of sexual dysfunction ranging from 50% to 65%.15. 27-31 Prev-
alence of sexual dysfunction in our patients was high (58.6%), sta-
tistically higher than in the control group (38.6%). This difference 
was maintained in the analysis of the association between diagnosis 
of psoriasis and each of the domains separately (desire, arousal, 
lubrication, orgasm, satisfaction, and pain), adjusted by age, race, 
schooling, and marital status, showing that sexual dysfunction is 
more frequent in the group of psoriasis patients in all the domains.
Analysis of the psoriasis group showed that patients report-
ing sexual dysfunction also presented more extensive skin lesions. 
This same relationship had been observed by Sampogna et al. in 
200732, later confirmed by Guenther et al. in 2011,33 although it is not 
a consensus.8, 13, 25, 30, 34-37
Various factors can impact the quality of sexual life in 
psoriasis patients, including side effects of medications, increased 
prevalence of comorbidities,38 lesion site, and symptoms of the skin 
condition itself, such as pruritis, psychological alterations, and the 
partner’s concerns33
Comorbidities were prevalent in the psoriasis group, as re-
ported in previous studies.39,40 Previous studies have reported a rela-
tionship between chronic diseases, especially rheumatic comorbid-* Results adjusted for age, race, schooling, and marital status
* significance: p-value <0.05
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ities, and sexual dysfunction.41,42 However, this relationship was not 
significant,  although patients with fibromyalgia presented lower 
FSFI scores, which is consistent with the high prevalence of sexual 
dysfunction described in patients with chronic pain.43 The absence 
of statistically significant results is probably due to the small num-
bers in each comorbidity, not allowing an adequate analysis of each 
condition.
The location of lesions also failed to show a significant as-
sociation with sexual dysfunction, consistent with the study by Van 
Dorssen et al.,44 although differing from results reported by other au-
thors, who pointed to genital involvement as an important factor in 
quality of sexual life.28, 37, 45 A possible explanation could be that the 
presence of lesion has less influence than local symptoms on quality 
of sexual life in these patients. Zamirska et al. assessed 93 women 
for vulvar pruritis or burning sensation (mons pubis, labia majora 
and minora, and clitoris).46 They found that 44.1% of women pre-
sented vulvar discomfort, 19.4%, pruritis, 10.8% burning sensation, 
and 14% both. However, only 22 women (23.7%) presented psoriatic 
lesions on the vulva, and 47.3% had a prior history of genital in-
volvement. The authors showed a significant correlation between 
vulvar discomfort and genital involvement of psoriasis.46
Note that prevalence of sexual dysfunction in the control 
group (38.6%) is slightly higher than the values found in other stud-
ies with healthy Brazilian women, where prevalence varied from 
30% to 35.7%.47,48 This could be explained by the different epidemi-
ological profiles of the study groups and the fact that women with 
chronic diseases, except for arthritis, or chronic drug use were not 
excluded.
Some limitations to the current study need to be addressed. 
First, although previous diagnoses of psychiatric disorders such as 
depression and anxiety were an exclusion factor, no specific psychi-
atric tests were applied.
Second, corroborating the literature, this group of patients 
with psoriasis also showed a high comorbidity rate (64%), includ-
ing diabetes mellitus and hypertension, chronic conditions that 
are known to be associated with increased sexual dysfunction. Al-
though prior sample calculation was performed to determine the 
number needed to assess the association between psoriasis and sex-
ual dysfunction, the calculation did not cover the determination of 
the possible causes of such dysfunction. Thus, to determine the real 
influence of factors like emotional alterations and comorbidities, es-
pecially rheumatic diseases, a larger sample would probably be nec-
essary. In addition, the complete exclusion of women with arthritis 
from the control group was intended to avoid the possibility of rare 
cases of psoriatic arthritis preceding cutaneous manifestation from 
being included erroneously in this group. However, this made the 
sample intentional, which can also be considered a bias.
CONCLUSION
Despite its limitations, our study was the first of its kind in 
female Brazilian patients, and the results proved important to con-
firm the impact of psoriasis on QoL, to identify the domains most 
affected, and to elucidate the relationship between this disease and 
alterations in sexual function. The high prevalence of sexual dys-
function in our patients highlights the need for a more comprehen-
sive approach to the health of women with psoriasis, beyond assess-
ment of their skin condition and the extent of the disease, including 
other QoL issues and specifically sexual function. q
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